Raymond James & Associates purchased a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 12,308 shares of the biotechnology company’s stock, valued at approximately $103,000.
Other institutional investors also recently added to or reduced their stakes in the company. UBS Group AG increased its position in Astria Therapeutics by 66,700.0% in the 1st quarter. UBS Group AG now owns 2,672 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,668 shares during the period. Citigroup Inc. bought a new position in Astria Therapeutics in the 1st quarter worth approximately $117,000. Bank of America Corp DE increased its position in Astria Therapeutics by 37.3% in the 4th quarter. Bank of America Corp DE now owns 11,112 shares of the biotechnology company’s stock worth $165,000 after buying an additional 3,020 shares during the period. Renaissance Technologies LLC bought a new position in Astria Therapeutics in the 2nd quarter worth approximately $41,000. Finally, Cubist Systematic Strategies LLC bought a new position in Astria Therapeutics in the 3rd quarter worth approximately $133,000. 87.85% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
ATXS has been the topic of several recent analyst reports. HC Wainwright dropped their price target on Astria Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, October 12th. Wedbush lowered their price objective on Astria Therapeutics from $25.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, October 13th.
Insiders Place Their Bets
In other Astria Therapeutics news, Director Perceptive Advisors Llc acquired 1,074,608 shares of Astria Therapeutics stock in a transaction on Monday, October 16th. The shares were bought at an average price of $6.51 per share, with a total value of $6,995,698.08. Following the completion of the purchase, the director now owns 1,652,371 shares in the company, valued at $10,756,935.21. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.40% of the company’s stock.
Astria Therapeutics Price Performance
Shares of ATXS stock opened at $4.49 on Tuesday. The firm has a market cap of $125.90 million, a price-to-earnings ratio of -1.84 and a beta of 0.90. The stock’s fifty day simple moving average is $6.51 and its 200 day simple moving average is $8.82. Astria Therapeutics, Inc. has a one year low of $4.27 and a one year high of $16.28.
Astria Therapeutics Company Profile
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.
- Five stocks we like better than Astria Therapeutics
- What is the Australian Securities Exchange (ASX)
- Catch the dip on Sociedad Quimica before earnings?
- Your Comprehensive Guide to Investing in Bank Stocks
- Can new GPT store spur generative AI monetization?
- How to Invest in Renewable Energy
- Energy looks to dominate markets with 3 oil and gas stocks
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.